Revenue segments as reported by the company.

Product, net

Revenue from anti-CD20 therapeutic programs

Other

Revenue from LEQEMBI Collaboration

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general and administrative

Amortization and impairment of acquired intangible assets

Collaboration profit sharing

(Gain) loss on divestiture of Hillerød, Denmark manufacturing operations

(Gain) loss on fair value remeasurement of contingent consideration

Acquired in-process research and development

Restructuring charges

Other (income) expense, net

Gain on sale of building

Gain on sale of PRV

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Biogen

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. It offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of multiple sclerosis, SPINRAZA for the treatment of spinal muscular atrophy, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Biogen reports Q4 results, focuses on cost-saving and growth strategies

Biogen's Q4 2022 performance showed a revenue decline but an increase in non-GAAP diluted EPS.
The company is prioritizing cost-saving initiatives and strategic product launches for growth.
Challenges include managing expenses, evaluating R&D programs, and balancing cost reductions with investments.
Opportunities lie in upcoming product launches, potential acquisitions, and expanding into new therapeutic areas.

Biogen reports $2.5B revenue in Q1 2023, focuses on transformative drug launches

Biogen's Q1 2023 performance showed revenue stability despite challenges in MS product revenue.
The company's strengths lie in its focus on transformative drug launches and Alzheimer's research advancements.
Challenges include reimbursement expectations and managing the transition period until 2025.
Opportunities exist in external growth strategies, asset prioritization, and commercial launches for LEQEMBI and Zuranolone.

Biogen reports mixed Q2 earnings, LEQEMBI approval drives optimism

Biogen's Q2 2023 Earnings Call showcased mixed financial performance, with a focus on cost-saving initiatives and pipeline advancements. LEQEMBI's approval and positioning as a maintenance treatment offer promise, while challenges in revenue decline and market adoption persist. Strategic initiatives and upcoming milestones provide opportunities for growth and portfolio enhancement.

Biogen reports solid Q3 earnings, eyes regulatory approvals and market expansion

Biogen's Q3 2023 performance reflects steady growth, strategic initiatives, and promising product developments.
Strengths in sustainable growth priorities, product launches, and cost optimization position Biogen for long-term success.
Challenges in market expansion and operational efficiency require focused efforts on infrastructure and process improvements.
Opportunities in regulatory approvals, market expansion, and therapeutic advancements pave the way for future growth and innovation.

Biogen reports Q4 revenue decline but eyes growth opportunities

Biogen's Q4 2023 performance saw revenue decline offset by growth in rare disease revenue.
The company's strategic strengths lie in new product launches, cost reduction initiatives, and a focused pipeline strategy.
Challenges include bottlenecks in product launches and trial size reductions, while opportunities exist in upcoming milestones and market expansion.
Overall, Biogen aims for sustainable growth with a diversified product portfolio and strategic market focus.

Biogen reports robust Q1 earnings, focuses on market expansion

Biogen's Q1 performance reflects strong earnings growth and strategic focus on new launches. Despite challenges in launch processes, the company is capitalizing on market penetration opportunities. With a robust balance sheet and ongoing market expansion efforts, Biogen is poised for continued growth and success.

Biogen reports robust Q2 earnings, eyes growth in new launches

Biogen's Q2 2024 earnings call highlighted strong financial performance, successful product launches, and strategic priorities for growth. While challenges in the MS franchise persist, the company remains focused on sustainable growth through R&D investments and acquisitions. Opportunities for growth exist in expanding product portfolios and upcoming data releases.

Biogen reports mixed Q3 results, focuses on growth strategies

Biogen's Q3 2024 performance was mixed, with revenue growth in key products but overall revenue decline.
The company faces challenges in certain product segments but shows strength in new product development.
Opportunities lie in expanding market presence, new product launches, and potential business development.
Despite profitability challenges, Biogen's focus on growth strategies positions it for future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Biogen Inc (NASDAQ: BIIB) posted Q2 adjusted EPS of $5.68 ahead of the consensus estimate of $4.55, but quarterly profit fell around 71% Y/Y to $448.5 million as competition intensified for the Company's flagship product, Tecfidera, a multiple sclerosis drug. Though sales of $2.8 billion came in above expectation of $2.6 billion, it decreased 25% Y/Y at actual currency and decreased 26% at constant currency.

Biogen's Q2 Profit Falls 70% As Tecfidera Competition Hits Topline

Biogen Inc on Thursday reported a 70.9% fall in quarterly profit as competition intensifies for multiple sclerosis drug Tecfidera, once the company's flagship treatment.

Biogen profit tumbles 71% on rising competition to multiple sclerosis drug

NOTE: ADUHELM TM (aducanumab-avwa) injection 100 mg/mL solution is indicated for the treatment of Alzheimer's disease. Treatment with ADUHELM should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population in which treatment was initiated in clinical trials. There are no safety or effectiveness data on initiating treatment at earlier or later stages of the disease than were studied. This indication is approved under accelerated approval based on reduction in amyloid beta plaques observed in patients treated with ADUHELM. Continued approval for this indication may be contingent upon verification of clinical benefit in confirmatory trial(s). Please see full Prescribing Information including Medication Guide .

An open letter to the Alzheimer's disease community from our Head of Research and Development, Alfred Sandrock, M.D., Ph.D.

Roche Holding AG

Aduhelm is expected to be a bestseller for Biogen and was the first Alzheimer's drug to be granted “accelerated approval,” a decision the regulator's experts criticized and said there was not enough evidence the drug actually worked.

Roche Is Discussing Alzheimer's Drug With FDA Following Regulators Controversial Approval Of Biogen's Aduhelm, CEO Says

Mirimus Inc has collaborated with Biogen Inc (NASDAQ: BIIB) to develop RNAi-based therapeutics targeting multiple, undisclosed neurological disease indications.  Terms of the collaboration are not disclosed.

Biogen, Mirimus Team Up For RNAi-Based Therapeutics For Neurological Indications

NEW YORK, July 21, 2021 /PRNewswire/ -- Mirimus, Inc., a pioneer in RNAi therapeutic design and CRISPR/Cas9 gene editing technology implementation, today announced a strategic collaboration with Biogen Inc. (NASDAQ: BIIB) focused on the development of RNAi-based therapeutics targeting multiple, undisclosed neurological disease indications. Terms of the collaboration between Mirimus and Biogen are undisclosed.

Mirimus, Inc. Forms Strategic Collaboration with Biogen to Develop RNAi-Based Therapeutics for Neurological Disease Indications

Investor focus is likely to be on commercialization plans for new Alzheimer's drug, Aduhelm when Biogen (BIIB) reports second-quarter earnings.

Biogen (BIIB) to Report Q2 Earnings: What's in the Cards?

This biotech company could be a diamond in the rough -- for investors who can tolerate its share price volatility.

Is It Too Late to Buy Biogen Stock?

Piper Sandler's Christopher Raymond argues that many neurologists still plan to prescribe Aduhelm and that insurers would largely cover the therapy's cost.

Biogen Is Still a Buy Despite Alzheimer's Drug Concerns, Analyst Says

AbbVie

Moderna

Pfizer

There are important things to watch with each of these stocks.

4 Large-Cap Healthcare Stocks You'll Want on Your Radar for the Second Half of 2021

Within the last quarter, Biogen (NASDAQ:BIIB) has observed the following analyst ratings: Last 30 Days 1 Month Ago 2 Months Ago 3 Months Ago Bullish 0 0 4 0 Somewhat Bullish 1 1 4 1 Indifferent 0 1 5 0 Somewhat Bearish 0 0 0 0 Bearish 0 0 0 0 In the last 3 months, 18 analysts have offered 12-month price targets for Biogen. The company has an average price target of $428.61 with a high of $647.00 and a low of $245.00.

What 18 Analyst Ratings Have To Say About Biogen

The medical community has not been entirely convinced of the U.S. FDA's decision to approve Biogen Inc's (NASDAQ: BIIB) Aduhelm drug to treat Alzheimer's last month. Some health insurers also declined coverage for Aduhelm The latest blow to the biotech firm came late on Thursday when Providence, Mount Sinai Health System, and the Cleveland Clinic […] The post Here's why three hospitals are refusing to treat patients with Biogen's new Alzheimer's drug appeared first on Invezz.

Here's why three hospitals are refusing to treat patients with Biogen's new Alzheimer's drug

Annovis Bio

Both are making Alzheimer's drugs, but only one can claim success as of today.

Better Biotech Stock: Biogen vs. Annovis Bio

Advanced Micro Devices

Invesco QQQ

U.S. indices were trading lower Thursday as investors weigh Fed Chair Powell's comments on inflation to the Senate banking panel.  The Invesco QQQ Trust Series 1 (NASDAQ:QQQ) fell by 0.7% to $360.52

AMD And Biogen Lead The QQQ Lower Thursday

The next big hurdle for Biogen will be receiving approval from health insurers to cover the costs of the drug.

Biogen falls 8% after 2 major hospital systems refuse to prescribe controversial Alzheimer's drug

BIIB stock is losing out today, as two major hospitals have declined to use Biogen's controversial new Alzheimer's drug on their campuses. The post BIIB Stock: The Drug Ban News That Has Biogen Stumbling Today appeared first on InvestorPlace.

BIIB Stock: The Drug Ban News That Has Biogen Stumbling Today

A pair of large hospitals have declined to administer Biogen Inc's (NASDAQ: BIIB) Alzheimer's treatment Aduhelm, Wall Street Journal reported. The Cleveland Clinic and Mount Sinai Health System in New York said they wouldn't administer the drug to patients amid a debate about the drug's effectiveness and whether the FDA followed missteps in approving the treatment.

Biogen Shares Are Trading Lower As Cleveland Clinic, Mount Sinai Decline To Aduhelm Administration

Acting FDA Commissioner Janet Woodcock pushed back against media questions about the agency's controversial approval of Alzheimer's treatment, Aduhelm developed by Biogen Inc (NASDAQ: BIIB) and Eisai Co Ltd (OTC: ESALY). During an interview at STAT's Breakthrough Science Summit, STAT journalist Nicholas Florko asked whether she was surprised about the broad label.

Biogen's Alzheimer's Drug Aduhelm Review Could Have Been Handled Differently, Says FDA Chief: STAT News

Acting FDA Commissioner Dr. Janet Woodcock pushed back against questions from a journalist about the approval of Biogen's Alzheimer's medication, Aduhelm.

FDA chief tells reporter 'move on' when pressed on Biogen Alzheimer's drug approval

Biogen partners with InnoCare Pharma for orelabrutinib, a BTK inhibitor with the potential of treating multiple sclerosis. The drug is currently undergoing phase II study.

Biogen (BIIB) In-Licenses Rights to Multiple Sclerosis Drug

Biogen Inc (NASDAQ: BIIB) is paying $125 million upfront to work on InnoCare Pharma Limited's orelabrutinib, a small oral molecule Bruton's tyrosine kinase inhibitor (BTKi) for multiple sclerosis. InnoCare is eligible to receive up to $812.5 million in potential milestone payments, as well as a percentage of sales, should it gain approval.

Biogen, InnoCare Collaborate On Multiple Sclerosis Candidate

CAMBRIDGE, Mass. and BEIJING, July 12, 2021 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and InnoCare Pharma Limited (HKEX: 09969) today announced that they have entered into a license and collaboration agreement for orelabrutinib, an oral small molecule Bruton's tyrosine kinase inhibitor (BTKi) for the potential treatment of multiple sclerosis (MS). Orelabrutinib is a covalent BTKi with high selectivity and the ability to cross the blood-brain barrier, and is currently being studied in a multi-country, placebo-controlled Phase 2 trial in relapsing-remitting MS.

Biogen and Innocare Announce License and Collaboration Agreement For Orelabrutinib, an Innovative CNS Penetrant BTK Inhibitor For the Potential Treatment of Multiple Sclerosis

Novartis

uniQure

SAGE Therapeutics

Several drugmakers have important clinical trial updates on the way.

Late-Stage Clinical Study Readouts Biotech Investors Should Watch

By Brandon Rakszawski, Senior ETF Product Manager The Morningstar Wide Moat Focus Index (the “Moat Index” or “Index”) underperformed the S&P 500® Index in June (1.15% vs. 2.33%, respectively).

Biogen's FDA Approval Takes Center Stage

• Acting commissioner refers agency to inspector general

News for Biogen Stock (BIIB)